Lake Street Capital Cuts MiMedx Group (NASDAQ:MDXG) Price Target to $10.00

MiMedx Group (NASDAQ:MDXG) had its price objective cut by Lake Street Capital from $12.00 to $10.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

MDXG has been the subject of a number of other research reports. Mizuho decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Price Performance

MDXG opened at $5.42 on Tuesday. The company has a fifty day moving average price of $6.62 and a two-hundred day moving average price of $6.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The firm has a market capitalization of $802.70 million, a PE ratio of 20.07 and a beta of 1.57. MiMedx Group has a 52 week low of $5.13 and a 52 week high of $9.30.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The business had revenue of $113.73 million during the quarter, compared to analysts’ expectations of $94.74 million. As a group, analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current year.

Insider Activity

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the transaction, the insider owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. CWM LLC raised its holdings in MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after purchasing an additional 1,892 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after buying an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of MiMedx Group in the 3rd quarter valued at $54,000. Headlands Technologies LLC acquired a new stake in MiMedx Group during the 2nd quarter worth $72,000. Finally, Osaic Holdings Inc. raised its stake in MiMedx Group by 57.2% during the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after acquiring an additional 4,708 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.